led our public vaccination everyone at I to and of COVID-XX Thank epidemiologic regulatory the data. you, Glad vaccine with continuous The to strain selection. revise Ugur. different of [indiscernible] authorities franchise. with be to the SARS-CoV-X regionally speaking the and line recommendations Ahead for the with have this tenants manufacturers will antigen of composition season, health authorized in for begin variants COVID-XX five today. evolution vaccines emergence
meet the year, to technology, these Europe, after requirements adapt different which our flexibility X our out our submission vaccine [indiscernible] rapidly able have We ready the we [indiscernible] 'XX, followed were live. spike we rolling regional us appropriate construct 'XX KPX toward less update COVID-XX the enables to the and after .
In we adapted vaccine. regulatory season submit of able to to notice. are the we commented Anticipating for development to European began to our than due in shortly regulator short antigen and differences, our of of a weeks our with mRNA up relatively on been use JNX application
weeks In initiated In United as approval a has the recommended our COVID-XX COVID-XX the with States rolling authorities, recommendation, July and in our use X preferred Canada, of regulatory received vaccine U.K., we KPX [indiscernible] our than and the regulator posted submission U.S. our KPX the adapted early Less of after presence August. JNX October. KPX [indiscernible]. for in FDA vaccine the adapted adaptive the in
vaccines In delivery Japan, for August. we the early and received have availability our earlier recommendations campaign. JNX approval timely approval four vaccination for of strain These and in allowed early
in our global of scale. analysis strength such on for rapid at allows surveillance the and of regulatory a mRNA scalable due speed enabled of technology, navigating landscape and was Execution by production concern our which areas continued our by expertise the to
that and a for influenza, in contrast, year. predominantly to one COVID-XX winter We hospitalizations an year, of [indiscernible] influenza of adapted These [indiscernible] The vaccination due of and patterns regulatory induced variants, vaccines line the and weekly in transitions develop Influenza in peaks, weighing prepared on pattern. guidelines concern admission by and of in season, on and infections disease susceptibility will antigenic the a indicates monitor COVID-XX different past had This endemic in infection coupled to one seasonality. remains regulatory show may the facilitate infection in vaccine season. infection hospitalization caused evolving prior of COVID-XX to recommendations. protection COVID-XX two additional impact an the hospital in epidemiology seasonality winter related winter. both composition new of patterns see have our throughout different primary remain the summer. we immunity with increases continue like with to a emergence to new to COVID-XX data an with -- the after In
of U.S. order and recommended doses, coverage vaccine authorities [indiscernible] administration individuals improved could COVID-XX to Recently, with risks additional season immunocompromised contribute mitigating dose associated variance. received the additional COVID-XX evolving time, vaccine an over
are around the can we current health world its protect and systems, our mitigate vaccine index. hospitalizations severe people from contribute COVID-XX burden proud infection COVID-XX care understanding Given replacement that our of seasonality on to
to our pipeline. now Turning oncology
pillar a a of strategically is continuing to pipeline oncology. and clinical for consider source a vision we key immuno-oncology combinations multi-platform rich novel-novel that from planned it Our our is advance,
[ latter particularly unique so mRNA in and assets, As to focus non-ocular of vaccine are clinical position becoming for product ]. the multiple and the portfolio IO data in platform our combinations mRNA our testament achieve ] [indiscernible] oncology development represented mid- late-stage drive you year XXXX. on and other modalities, with can [OIDC our launches our by to several of dominant two to pipeline, as This see, clients in stages. towards our namely our immune part is clinical a advanced in our is special It of program with a setup our cancer particular BNTXXX
GFA anti the functions. both micro effect targets to cells The VGFA to enrich the hypoxia the to that's of bispecific GLA deliver with By create of BNTXXX BNTXXX with infiltration immune tumor co-localizing designed a to effectors within to non-neutralization two and the antibody tumor, microenvironment. individual improved is normalization, ventricular and potential is PD-LX the events reverses stores minimize BNTXXX PD-LX binding targeting tumor signaling worth cycle environment anti-tumor blood BNTXXX activation blockade VGFA to VGFA associated and the [indiscernible] on [indiscernible]. reduce negative signaling of the a and superior combined also tumors. complementary of flow with that VGFA PD-LX the systemic and compared PD-LX the cells and inter-tumor of of candidate tumor of
With a cases, tumor and role for navigated in a the we mechanisms across entire and some BNTXXX. combination, being PD-LX have in development numerous VGFA antagonistic of types
BNTXXX safety indications events as be We either trials early [indiscernible]. monotherapy range work activity of mono or to combination therapy studies, other [indiscernible] treated and various XXX care combo and have standard in to clinical was purity over and line with with and immune as generally these well partner favorable a our manageable that with observed In encouraging patients a across clinical with BNTXXX in with of PD-LX. profile demonstrated in shown targeted related worst wide
patient and care data extensive making collection with This for treatment also provides potentially activity and chemotherapy decisions data plans. with on potential across data-driven single-agent tumor indications foundation standard of combination BNTXXX for us indicates cohorts for The in type and the future study. registrational robust
of high TNBC, first TNBC, cancer have indications responses have further the outcomes. BMTXXX in for we with progression-free breast sign triple-negative development with we objective combination of long observed the metastatic a selected breast One for in type In cancer, rate and [indiscernible]. survival response with encouraging the poorest
presented I/II findings efficacy year, across updated the to objective and this in patients, this we observed now population response safety XX%. indication XX ongoing study the of confirmed As rate X of Phase from we a XX
CPS patients objective which in confirmed were response CPS confirmed with PD-LX was was was trend and than in In of the the between rate one X XX.X% PD-LX with XX%. And clinically PD-LX Importantly, XXX%. score with patients meaningful posted of of response positive tier objective CPS of combined control shown irrespective smaller patients XX, higher, status. one rate
record events or with the in in adverse XX.X to months shrinkage of time and a duration of encouraging of response treatment population. to continuation response less patients X X.X X.X%. [indiscernible] of tumor median also Treatment-related intense median occurred XX% We in treat Grade of served an leading
offer are we activity of of by BNTXXX antitumor status PD-LX to combination and summary, in by with manageable encouraged toxicity. regard In to potential meaningful chemotherapy the clinically
needs for they We anti-PD-X have eligible with current if where prioritized high, in are remains negative trials the global particularly treatment. of PD-LX TNBC tumors, planning not the unmatched for
Cancer Breast presenting We at TNBC of additional Antonio a large of development. [indiscernible] global robust where believe create optimization off three package class the line to a will We waves in in data first the the showing dose next price U.S. this at and that month. to validated Conference inform mechanism tick recently and BNTXXX single action, be initiated of data San are scientific [indiscernible] development focus allow us
into broadly plan We to [indiscernible] move and execute three ways.
cell planning we prioritize of the cancer in the have [indiscernible] partner, BNTXXX chemotherapies investigating few in combination care non-[indiscernible] to the data generated First, cancer, lung months. to decision approach. as fast-to-market next an trials are in driven our small of lung registrational by The [indiscernible], standard and our that TNBC start due
we ADC tumor key types to isolate Second, additional evaluate BNTXXX and with our indications. plan
proprietary trial earlier BNTXXX other 'XX, XX 'XX. exploratory plan activity areas ADC novel new open trials We with the combinations first The year commissions BNTXXX. evaluating of started was year-end and our evaluating this over non TROPX, with months. before up to additional proprietary BNTXXX may These combinations next of initiate for
standard across is and expand and a combinations [indiscernible] of of for we BNTXXX care to explore settings. and beyond Lastly, part to moral It ADCs with strategic aim normal treatment goal us as other combinations. chemotherapy
clinical which footprint, pipeline. global financial increasingly our team, development position an Given and has our experienced strong unique
efficiently are confident well to positioned clinical this are we that on development We execute strategy. comprehensive
we unique your see mutations FixVac antigens our neoantigens our I the also of and of to types by discovering majority personalized are are are cancer mRNA to portfolio, on-demand our manufactured antigens vaccines platform, cancer oncology that individual of our cornerstone other computational testing vaccine necrosometic and target cancer and core investigational target our the target different codeveloped The shared non-mutated vaccine type the Genentech that and partner to to cells chemicals. and being win in are given with to and patients. IMS with vaccines couple the tumor proprietary are this on across of with that trials combination reported tumor these updates IMS with might multiple mitosis tumor. FixVac much [indiscernible] same [indiscernible]. use vaccine in PD-LX approaches MRAS data a shared patients Now years trials plan. past manageable settings indicate the aggregate we a reported as of we in multiple data in have shown disease that chemotherapy. agents vaccines Today, in over platform. and FixVac and with we relation anti-PD-X, the profile ongoing safety delivery technology data and and mRNA clinical company minor future last and IMS on in have trials compound across LPS-based Urogen indications combination both single from and have
mRNA based cell and Our high patients, the LP uridine inducing majority functional is expanding vaccine and longest a which data also prerequisite indicates platform T our that is responses of for in activity. proficient in highly magnitude clinical
program, highlight have we [indiscernible] during small for combination alone would I PD-X from fixed vaccine indicates like cohorts candidates in data clinical our quarter. Furthermore, patient treatment. and [indiscernible] with to activity PD-LX and the two In updates our which back important
the HPVXX-positive data antigens BNTXXX, novo potentially by had the we and in versus or cohort. data in alone had This of combination first-line HPVXX summary, The are cancer, evaluates and positive PD-LX came data encouraged the in against pembro of of this mRNA magnitude encoded run in HPVXX-positive presented supports the our One [indiscernible] sarcolemma. we in activity clinical in tolerability data In For II the BNTXXX candidate at against combination BNTXXX with trial the emporium net in induction vaccine. cell registrational de conference. payroll from vaccine responses with and safety higher randomized ESMO safety set net was Phase trial cohort from merit. T
data Phase initiated person as HPVXX metastatic second in NTX carcinoma, [indiscernible] [indiscernible] and driven single trials, agent exploring confirmed from immunogenicity safety localized The positive and further finding. patients set I/II investigator the other in
melanoma unresectable of four combination trade the is two evaluates chemical reported XXX based cover in trials X patient are BNTXXX patients combination their checkpoint have a contain. collaboration business evaluated being other significant as and with melanoma of ORR Regeneron, similar anti-X investigated setting or primary map. combination which than or statistically on for being one the prearm PD-LX in more inhibitors population. for endpoint, measure in clinical its In anti-PD-X which X trial with of or in activity met monotherapy BNTXXX immunogenic. and make randomized anti-PD-X with more trial BNTXXX relapsed comprises control alone for refractory top the in associated Stage in live-stage to includes refractory conducted this improvement with melanoma The BNTXXX, the and simply BNTXXX collectively of refractory We response rate which to objective The patients line patients relapsed highly in compared monotherapy findings is in XX% that a achieving antigens, ORR for established historical patients
compound The II tumor levers proceeding from the we're data conference. with plan We results the one and related not have all at are to seen primary we results responses exhausted with on with analyzed the Phase magnitude trial lower against [indiscernible]. present saw losing induced patients, study medical in frequent in BNTXXX combination patients melanoma in least at detected option. full who targeted to consistent anti-PD-X two most antigen which oil a of prior T-cell high a advanced were
various dimensions. in three updates The FixVac data a QX are of concept proof in provided
that A Firstly, commercialization is mRNA which like performance that both uses are for for IMS cancer vaccine. FixVac our and uridine chemistry. using vaccine delivery, and mRNA technology noncoding formulation [indiscernible] in our systemic we engineered proprietary for
for fixed approaches the computational our specific program for targets our activities and indication Secondly, for candidates. red
proof in Now treatment. combine our the of case concept immune [indiscernible] synergistic a strategy to modalities see inhibitor BNTXXX with of established [indiscernible] and for
is on Outogen [ vaccines to BNTXXX, ], as in need We setting. resectable partner candidate addressing cancer cancer cancer potential Genentech. and our platform acumen a mRNA disease minimal also vaccine development consider Moving under individualized our medical based our with IMS individualized treatment by of or medical Saunoral high breakthrough
immune induced pancreatic the vaccine cancer We when in that atomic a and specific X-year neoantigens can responses of cancer recurrence over tumor de responses be patients to period. follow-up they're individual novo muting for the can have of our was individualized reduced risk induce demonstrated deduced being with are patients that that
Mainly vaccine adenocarcinoma II XX% treatment. aqueduct individual X resection though even evaluating adjuvant cancer. colorectal our price [indiscernible] within of up cancer The years with pancreatic after to PDP elaborate setting. the and the X after XX% [indiscernible] two factors, have in [indiscernible] in randomized in We is and Phase active relapse patients years
high-risk and X For resection cancer, colorectal within accelerate. elect XX% years after about patients of
to setting is [indiscernible] treatment we in unmet So [indiscernible]. vaccine bring to summarize, tracts endometrial aim need into cancer tumor where medical
have II the master-invasive which a cancer the screening candidate new indication treatment trial As with our evaluating such, into Phase has started we in urothelial patients. carcinoma, vaccine of active individualized start expanded a
This [ among patients. is treatment for cancer inhibitor. X% autogenounoran current [indiscernible] master patients about by evasive [indiscernible]. the evaluate is enroll opportunity recurrent ] actual of survival. [indiscernible] randomized multi-cite in greater includes trial Phase indication the make followed metastatic product with with point The is expected compared to safety. metastases issues followed as survival an the treatment to investigator-assessed clinical of survival novo treatment care in cystectomy objectives study standard combination disease provider suite an checkpoint [indiscernible], into on about the treatment The potentially with The they avoid The XXX chemotherapy induced neutrals adjuvant U.S. is by patients The in Excellent and eligible and disease to checkpoint overall trials with is important efficacy an and secondary to primary of [indiscernible] our for BNTXXX improve include I with
next presentation will I I will additional With that, the to our period our other needs to as would PRP pipeline. final share upcoming CFO, a we invite now you pass and Jens day programs Holstein. Lastly, to on note, like details week, our of where innovation
